Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8435774 | 0.86 | PSIP1 (0.41) | PSIP1GAAHSD11B1ALDH1A1TDP1 | |
| SCHEMBL28206252 | 0.82 | PSIP1 (0.34) | PSIP1HSD11B1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL10606555 | 0.81 | THRB (0.42) | PSIP1ALDH1A1 | |
| SCHEMBL28245872 | 0.81 | THRB (0.42) | PSIP1ALDH1A1 | |
| SCHEMBL8926410 | 0.81 | THRB (0.42) | PSIP1ALDH1A1 | |
| SCHEMBL4524280 | 0.79 | CA2 (0.47) | PSIP1HSD11B1ALDH1A1POLB | |
| SCHEMBL7863515 | 0.79 | HSD11B1 (0.33) | PSIP1HSD11B1ALDH1A1TDP1HSD17B10 | |
| SCHEMBL28640869 | 0.79 | HTR6 (0.33) | PSIP1HSD11B1HTR6 | |
| SCHEMBL28055 | 0.78 | ENPP2 (0.39) | PSIP1HTR6 | |
| SCHEMBL28129004 | 0.78 | LOX (0.40) | PSIP1ALDH1A1TSHRSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536635-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-30 | — | — | CN | claimed |
| CN-115521264-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-27 | — | — | CN | claimed |
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| EP-3019490-B1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2020-06-03 | — | — | EP | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| CN-108912066-A | Therapeutical active compound and its application method | 安吉奥斯医药品有限公司 | 2018-11-30 | — | — | CN | claimed |
| US-10111878-B2 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | claimed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | claimed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | claimed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | claimed |
| CN-1946700-A | Trisubstituted ureas as cytokine inhibitors | PROCTER & GAMBLE (US) | 2007-04-11 | — | — | CN | claimed |
| EP-1633733-A4 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | UNIV TENNESSEE RES CORP (US) | 2007-02-28 | — | — | EP | claimed |
| US-7169942-B2 | agonists or antagonists; treatment for neuroinflammatory pathologies involving demyelinization, viral encephalitis, cerebrovascular accidents, cranial trauma, ocular disorders, pulmonary disorders, allergic diseases, inflammatory conditions, immune system disorders, central nervous system diseases, etc. | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-30 | — | — | US | claimed |
| JP-2007501279-A | — | — | 2007-01-25 | — | — | JP | claimed |
| CN-1845894-A | phenoxyacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-10-11 | — | — | CN | claimed |
| EP-1633733-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004113320-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040242593-A1 | Cannabinoid derivatives, methods of making, and use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10111878-B2 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer | IDH2, IDH3B, IDH3A | PSIP1 3964/4885GAA 2440/4885HSD11B1 1187/4885 |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | PSIP1 3824/4885GAA 1016/4885HSD11B1 2180/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | PSIP1 3030/4885GAA 456/4885HSD11B1 1417/4885 |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | PSIP1 999/4885GAA 81/4885HSD11B1 65/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | PSIP1 3030/4885GAA 456/4885HSD11B1 1417/4885 |
| US-20040242593-A1 | Cannabinoid derivatives, methods of making, and use thereof | CNR2, CNR1, GPR18 | PSIP1 3604/4885GAA 4311/4885HSD11B1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.